269 related articles for article (PubMed ID: 28634131)
1. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
3. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
[TBL] [Abstract][Full Text] [Related]
4. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.
Cortesi PA; Belli LS; Facchetti R; Mazzarelli C; Perricone G; De Nicola S; Cesana G; Duvoux C; Mantovani LG; Strazzabosco M;
J Viral Hepat; 2018 Jul; 25(7):791-801. PubMed ID: 29406608
[TBL] [Abstract][Full Text] [Related]
5. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Tapper EB; Hughes MS; Buti M; Dufour JF; Flamm S; Firdoos S; Curry MP; Afdhal NH
Transplantation; 2017 May; 101(5):987-995. PubMed ID: 27495755
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy.
Bethea ED; Samur S; Kanwal F; Ayer T; Hur C; Roberts MS; Terrault N; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):739-747.e8. PubMed ID: 30138735
[TBL] [Abstract][Full Text] [Related]
7. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Njei B; McCarty TR; Fortune BE; Lim JK
Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
9. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.
Chhatwal J; Samur S; Bethea ED; Ayer T; Kanwal F; Hur C; Roberts MS; Terrault N; Chung RT
Hepatology; 2018 Jun; 67(6):2085-2095. PubMed ID: 29222916
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
[TBL] [Abstract][Full Text] [Related]
11. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
12. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
17. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
18. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
Chhatwal J; He T; Hur C; Lopez-Olivo MA
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
Due OT; Thakkinstian A; Thavorncharoensap M; Sobhonslidsuk A; Wu O; Phuong NK; Chaikledkaew U
Value Health; 2020 Sep; 23(9):1180-1190. PubMed ID: 32940236
[TBL] [Abstract][Full Text] [Related]
20. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
